Marine actinomycete crude extracts with potent TRAIL-resistance overcoming activity against breast cancer cells

Elmallah,Mohammed I.Y.; Micheau,Olivier; Eid,Mennat Allah G.; Hebishy,Ali M.S.; Abdelfattah,Mohamed S.

doi:10.3892/or.2017.5595

Marine actinomycete crude extracts with potent TRAIL-resistance overcoming activity against breast cancer cells

Authors:
- Mohammed I.Y. Elmallah
- Olivier Micheau
- Mennat Allah G. Eid
- Ali M.S. Hebishy
- Mohamed S. Abdelfattah
View Affiliations

Affiliations: Marine Natural Products Unit (MNPRU), Faculty of Science, Helwan University, 11795 Ain Helwan, Cairo, Egypt, LNC, INSERM, UMR1231, F-21079 Dijon, France
Published online on: April 21, 2017 https://doi.org/10.3892/or.2017.5595
Pages: 3635-3642

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, as it can kill tumor cells selectively. In our search of bioactive natural products to overcome TRAIL-resistance, we isolated 47 actinomycete strains from different sediments and seawater samples collected from the Red Sea coast in Egypt and found four crude extracts (EGY1, EGY3, EGY24 and EGY34) displaying TRAIL sensitizing activity in the resistant breast cancer cell line MDA-MB-231. None of these crude extracts exhibited cytotoxic effect on normal mouse embryonic fibroblasts (MEF), with the exception of EGY34. Analysis of the signaling pathways underlying the sensitization of MDA-MB-231 cells to TRAIL-induced apoptosis, by western blotting, revealed that all crude extracts facilitated initiator caspase‑8/-10 activation upon TRAIL stimulation, but that in addition, EGY3 and EGY34, alone, induced strong ER-stress activation, with the appearance of BiP in the cytosolic extracts. Our results pave the way to the discovery and the development of marine-derived drugs for cancer therapy.

View Figures

View References

1	Almasan A and Ashkenazi A: Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14:337–348. 2003. View Article : Google Scholar : PubMed/NCBI
2	Micheau O, Shirley S and Dufour F: Death receptors as targets in cancer. Br J Pharmacol. 169:1723–1744. 2013. View Article : Google Scholar : PubMed/NCBI
3	Peter ME and Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26–35. 2003. View Article : Google Scholar : PubMed/NCBI
4	Kelley SK and Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 4:333–339. 2004. View Article : Google Scholar : PubMed/NCBI
5	Falschlehner C, Emmerich CH, Gerlach B and Walczak H: TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol. 39:1462–1475. 2007. View Article : Google Scholar : PubMed/NCBI
6	Griffith TS and Lynch DH: TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 10:559–563. 1998. View Article : Google Scholar : PubMed/NCBI
7	Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, Chiao P and Fang B: Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther. 9:666–673. 2004. View Article : Google Scholar : PubMed/NCBI
8	Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G and Klein J: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 61:82–90. 2008. View Article : Google Scholar : PubMed/NCBI
9	Henson ES, Johnston JB and Gibson SB: The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma. 49:27–35. 2008. View Article : Google Scholar : PubMed/NCBI
10	Humphreys RC and Halpern W: Trail receptors: Targets for cancer therapy. Adv Exp Med Biol. 615:127–158. 2008. View Article : Google Scholar : PubMed/NCBI
11	Ndozangue-Touriguine O, Sebbagh M, Mérino D, Micheau O, Bertoglio J and Bréard J: A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene. 27:6012–6022. 2008. View Article : Google Scholar : PubMed/NCBI
12	Thorburn A, Behbakht K and Ford H: TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them. Drug Resist Updat. 11:17–24. 2008. View Article : Google Scholar : PubMed/NCBI
13	Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A: TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kaufmann T, Strasser A and Jost PJ: Fas death receptor signalling: Roles of Bid and XIAP. Cell Death Differ. 19:42–50. 2012. View Article : Google Scholar : PubMed/NCBI
15	Srivastava RK: TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia. 3:535–546. 2001. View Article : Google Scholar : PubMed/NCBI
16	Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, et al: Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ. 18:700–711. 2011. View Article : Google Scholar : PubMed/NCBI
17	Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T and Micheau O: Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica. 97:38–46. 2012. View Article : Google Scholar : PubMed/NCBI
18	Morlé A, Garrido C and Micheau O: Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. Cell Death Dis. 6:e16332015. View Article : Google Scholar : PubMed/NCBI
19	Blunt JW, Copp BR, Munro MH, Northcote PT and Prinsep MR: Marine natural products. Nat Prod Rep. 23:26–78. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mayer AM, Rodríguez AD, Berlinck RG and Hamann MT: Marine pharmacology in 2003-4: Marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol. 145:553–581. 2007. View Article : Google Scholar : PubMed/NCBI
21	Williams PG: Panning for chemical gold: Marine bacteria as a source of new therapeutics. Trends Biotechnol. 27:45–52. View Article : Google Scholar : PubMed/NCBI
22	Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT and Prinsep MR: Marine natural products. Nat Prod Rep. 26:170–244. 2009. View Article : Google Scholar : PubMed/NCBI
23	Fenical W, Sethna KM and Lloyd GK: Marine microorganisms as a developing resource for drug discovery. Pharm News. 9:489–494. 2002.
24	Abdelfattah MS: A new bioactive aminophenoxazinone alkaloid from a marine-derived actinomycete. Nat Prod Res. 27:2126–2131. 2013. View Article : Google Scholar : PubMed/NCBI
25	Abdelfattah MS, Ishikawa N, Karmakar UK, Yamaku K and Ishibashi M: New phenazine analogues from Streptomyces sp. IFM 11694 with TRAIL resistance-overcoming activities. J Antibiot (Tokyo). 69:446–450. 2016. View Article : Google Scholar : PubMed/NCBI
26	Abdelfattah MS, Toume K and Ishibashi M: Yoropyrazone, a new naphthopyridazone alkaloid isolated from Streptomyces sp. IFM 11307 and evaluation of its TRAIL resistance-overcoming activity. J Antibiot (Tokyo). 65:245–248. 2012. View Article : Google Scholar : PubMed/NCBI
27	Abdelfattah MS, Ishikawa N, Karmakar UK and Ishibashi M: Sulfotanone, a new alkyl sulfonic acid derivative from Streptomyces sp. IFM 11694 with TRAIL resistance-overcoming activity. J Nat Med. 70:266–270. 2016. View Article : Google Scholar : PubMed/NCBI
28	Abdelfattah MS, Kazufumi T and Ishibashi M: New pyranonaphthoquinones and a phenazine alkaloid isolated from Streptomyces sp. IFM 11307 with TRAIL resistance-overcoming activity. J Antibiot (Tokyo). 64:729–734. 2011. View Article : Google Scholar : PubMed/NCBI
29	Abdelfattah MS, Kazufumi T and Ishibashi M: Izumiphenazines A-C: Isolation and structure elucidation of phenazine derivatives from Streptomyces sp. IFM 11204. J Nat Prod. 73:1999–2002. 2010. View Article : Google Scholar : PubMed/NCBI
30	Elmallah MIY and Micheau O: Marine drugs regulating apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Mar Drugs. 13:6884–6909. 2015. View Article : Google Scholar : PubMed/NCBI
31	Hayakawa M and Nonomura H: Humic acid-vitamin agar, a new medium for the selective isolation of soil actinomycetes. J Ferment Technol. 65:501–509. 1987. View Article : Google Scholar
32	Kuester E and Williams ST: Selection of media for the isolation of streptomycetes. Nature. 202:928–929. 1964. View Article : Google Scholar : PubMed/NCBI
33	Kieser T, Bibb MJ, Buttner MJ, Chater KF and Hopwood DA: Practical Streptomyces Genetics. 2nd. The John Innes Center Foundation; Norwich: 2000
34	Abdelfattah MS, Elmallah MIY, Hawas UW, El-Kassema LT Abou and Eid MAG: Isolation and characterization of marine-derived actinomycetes with cytotoxic activity from the Red Sea coast. Asian Pac J Trop Biomed. 6:651–657. 2016. View Article : Google Scholar
35	LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75. 2003. View Article : Google Scholar : PubMed/NCBI
36	Takahashi Y and Omura S: Isolation of new actinomycete strains for the screening of new bioactive compounds. J Gen Appl Microbiol. 49:141–154. 2003. View Article : Google Scholar : PubMed/NCBI
37	Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT and Prinsep MR: Marine natural products. Nat Prod Rep. 24:31–86. 2007. View Article : Google Scholar : PubMed/NCBI
38	Van Slambrouck S, Daniels AL, Hooten CJ, Brock SL, Jenkins AR, Ogasawara MA, Baker JM, Adkins G, Elias EM, Agustin VJ, et al: Effects of crude aqueous medicinal plant extracts on growth and invasion of breast cancer cells. Oncol Rep. 17:1487–1492. 2007.PubMed/NCBI
39	Ferretti C, Marengo B, De Ciucis C, Nitti M, Pronzato MA, Marinari UM, Pronzato R, Manconi R and Domenicotti C: Effects of Agelas oroides and Petrosia ficiformis crude extracts on human neuroblastoma cell survival. Int J Oncol. 30:161–169. 2007.PubMed/NCBI
40	Oliveras-Ferraros C, Fernández-Arroyo S, Vazquez-Martin A, Lozano-Sánchez J, Cufí S, Joven J, Micol V, Fernández-Gutiérrez A, Segura-Carretero A and Menendez JA: Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. Int J Oncol. 38:1533–1547. 2011.PubMed/NCBI
41	Szliszka E, Zydowicz G, Janoszka B, Dobosz C, Kowalczyk-Ziomek G and Krol W: Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis. Int J Oncol. 38:941–953. 2011.PubMed/NCBI
42	Abdelhamed S, Yokoyama S, Hafiyani L, Kalauni SK, Hayakawa Y, Awale S and Saiki I: Identification of plant extracts sensitizing breast cancer cells to TRAIL. Oncol Rep. 29:1991–1998. 2013.PubMed/NCBI
43	Lee YS, Lee DG, Lee JY, Kim TR, Hong SS, Kwon SW and Kim YS: A formulated red ginseng extract upregulates CHOP and increases TRAIL-mediated cytotoxicity in human hepatocellular carcinoma cells. Int J Oncol. 43:591–599. 2013.PubMed/NCBI
44	Thorburn A: Death receptor-induced cell killing. Cell Signal. 16:139–144. 2004. View Article : Google Scholar : PubMed/NCBI
45	Rao L, Perez D and White E: Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol. 135:1441–1455. 1996. View Article : Google Scholar : PubMed/NCBI
46	Sano R and Reed JC: ER stress-induced cell death mechanisms. Biochim Biophys Acta. 1833:3460–3470. 2013. View Article : Google Scholar : PubMed/NCBI